Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Neurology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Drug-induced movement disorders and tardive dyskinesia

Neurology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Laryngeal or severe acute dystonia, oculogyric crisis with airway concern, hyperthermia with rigidity and autonomic instability, severe serotonin toxicity, rhabdomyolysis, profound dysphagia or suicidal akathisia requires emergency ABCDE care. Stop the suspected culprit, obtain senior toxicology, psychiatry or critical-care help and treat the specific syndrome without waiting for a movement-clinic appointment.

Overview

Recognise acute dystonia, akathisia, parkinsonism and tardive dyskinesia from their phenomenology and exposure timeline, separate them from psychiatric symptoms, and stop iatrogenic escalation while treating emergencies and preserving mental-health stability.

The same dopamine-blocking exposure can produce several movement syndromes at different times. Acute dystonia is patterned and sustained, often involving the neck, jaw, eyes or tongue. Akathisia is subjective as well as visible; ask whether movement relieves an unbearable inner restlessness. Parkinsonism reduces movement and facial expression and may be confused with negative symptoms or depression. Tardive dyskinesia is delayed and often hyperkinetic, with chewing, tongue protrusion, grimacing and limb or trunk movements. Tardive dystonia and akathisia also occur.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
NeurologyOriginal SBA

Reassessment after an intramuscular antidote

A 23-year-old receives 1 mg intramuscular benztropine for a prochlorperazine-induced oculogyric crisis. Painful posturing persists, but the airway and observations remain stable. The prescription allows a repeat within the daily maximum. At what interval after the first injection does SPS advise repeating an unresponsive IM dose?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Neurology topics →
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE CG178 antipsychotic recommendationsShared antipsychotic choice and systematic extrapyramidal and physical-health monitoring.
  • MHRA metoclopramide neurological safetyUK warning on acute extrapyramidal reactions and tardive dyskinesia from a common antiemetic.
  • NICE NG127 adult involuntary movement referralNational recognition and neurological referral principles for abnormal movements.
  • NICE NG215 medicine withdrawal recommendationsGeneral shared-decision and safe withdrawal principles relevant to adjunct sedatives.
  • NHS SPS benztropine injection for acute dystonic reactionsCurrent injection availability, adult doses and unlicensed-product safeguards.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting review
Risk relates to potency, dose, duration, age, underlying neurological disease, diabetes and cumulative exposure, but no antipsychotic is risk free. Acute dystonia is more common in younger people and after rapid dose increase. Drug-induced parkinsonism is common in older adults and can unmask preclinical Parkinson disease; persistence after withdrawal may justify dopaminergic imaging or specialist reassessment. Tardive movements can be masked temporarily by increasing the blocker, a misleading improvement that increases long-term exposure.

Care must balance neurological harm and psychiatric relapse. The prescriber, patient and mental-health team should review whether the medicine remains needed, whether dose reduction is safe, and whether a lower-risk agent such as clozapine is appropriate. Off-label VMAT2 treatment and antipsychotic changes require specialist authorisation under local psychiatry, pharmacy, toxicology and movement-disorder protocols.

Key points

  • Acute dystonia usually appears within hours to several days of a dopamine-blocking medicine or dose increase and causes painful sustained neck, jaw, eye, tongue or trunk postures.
  • Akathisia is a distressing inner inability to keep still with pacing, rocking or repeated leg movement; it is commonly mistaken for agitation or worsening psychosis.
  • Drug-induced parkinsonism develops over days to months with bradykinesia, rigidity and often bilateral symptoms, although asymmetry does not completely exclude a medication contribution.
  • Tardive dyskinesia follows cumulative dopamine-receptor-blocking exposure and commonly produces repetitive oro-bucco-lingual, chewing, choreiform or athetoid movements that can persist after the drug stops.
  • Antipsychotics are major causes, but metoclopramide and prochlorperazine are important non-psychiatric exposures; reconcile antiemetics, depot injections and remote courses.
  • Neuroleptic malignant syndrome combines dopamine-blocker exposure or dopaminergic withdrawal with rigidity, hyperthermia, altered mental state, autonomic instability and often raised creatine kinase.
  • Document a baseline and serial movement examination during antipsychotic treatment because patients may not notice early tongue or finger movements.

Aetiology

01

Dopamine-receptor blockade

Antipsychotics and dopamine-blocking antiemetics can cause acute dystonia, akathisia and parkinsonism, particularly after initiation, dose increase or parenteral exposure.

02

Cumulative tardive exposure

Longer dopamine-blocker exposure increases risk of persistent oro-bucco-lingual, choreiform or dystonic movements, although tardive syndromes can appear after shorter courses.

03

Dopaminergic withdrawal and other medicines

Abrupt withdrawal of Parkinson treatment can cause severe rigidity, while lithium, valproate, stimulants and serotonergic medicines produce tremor, myoclonus or other movement phenotypes.

Pathophysiology

  1. 1
    Acute pathway imbalance

    Dopamine blockade disrupts basal-ganglia balance, causing excessive cholinergic influence and patterned dystonia or reduced movement with rigidity.

  2. 2
    Subjective motor drive

    Altered striatal signalling can generate an uncomfortable internal need to move, expressed as pacing, rocking and inability to remain still in akathisia.

  3. 3
    Receptor and circuit adaptation

    Chronic blockade promotes receptor supersensitivity and maladaptive plasticity, allowing repetitive involuntary tardive movements that may persist after the medicine stops.

Clinical features and red flags

Acute dystoniaRed flag

Torticollis, jaw spasm, tongue protrusion, opisthotonus or sustained upward eye deviation soon after dopamine blockade is a painful acute dystonic reaction until an alternative is shown.

AkathisiaRed flag

Subjective inner torment with pacing, shifting weight and inability to sit after antipsychotic initiation or increase should be named and assessed for self-harm rather than dismissed as non-compliance.

Drug-induced parkinsonism

Bradykinesia, reduced expression, rigidity, shuffling and tremor emerging during dopamine-receptor blockade suggests medication effect, particularly when bilateral and temporally linked.

Tardive dyskinesia

Persistent lip smacking, chewing, tongue, facial, distal limb or trunk movements after months or years of exposure support a tardive syndrome and require structured severity recording.

Neuroleptic malignant syndromeRed flag

Fever, generalised rigidity, confusion, tachycardia, labile blood pressure and raised creatine kinase after dopamine blockade is a life-threatening systemic syndrome.

Investigations

  1. 01
    Complete exposure timelineFirst step
    Why
    Link syndrome onset to antipsychotic, antiemetic, antidepressant, dopaminergic and withdrawal events.
    Interpretation and limitations
    Include depot dates, as-required administration, emergency antiemetics and medicines recently stopped. A delayed tardive syndrome may become more visible after dose reduction.
  2. 02
    Structured movement examination
    Why
    Separate dystonia, akathisia, parkinsonism and dyskinesia and create a reproducible baseline.
    Interpretation and limitations
    Observe face, mouth, tongue, hands, trunk, gait and seated rest; pair an objective scale with the patient’s subjective distress and functional impact.
  3. 03
    Acute physiological and laboratory assessment
    Why
    Identify neuroleptic malignant syndrome, serotonin toxicity and complications of severe movement.
    Interpretation and limitations
    Check temperature, consciousness, autonomic observations, hydration, renal function, electrolytes, CK, blood count and liver tests as indicated; severe syndromes remain clinical diagnoses requiring immediate treatment.
  4. 04
    Neurological reassessment after medicine change
    Why
    Determine whether persistent parkinsonism reflects unmasked degenerative disease or tardive movement remains despite withdrawal.

Differential diagnosis

01

Idiopathic Parkinson disease

Asymmetric rest tremor, non-motor prodrome and sustained levodopa response favour degenerative disease, although dopamine blockers can unmask previously subclinical parkinsonism.

02

Psychiatric agitation

Goal-directed restless behaviour linked to thought or emotion differs from the distressing inner motor urge of akathisia; careful subjective history prevents dose escalation.

03

Neuroleptic malignant syndrome

Fever, altered mental state, generalised rigidity and autonomic instability indicate a life-threatening systemic syndrome rather than uncomplicated drug-induced parkinsonism.

04

Primary chorea, dystonia or tics

Family history, childhood onset, stereotyped urge or movement preceding drug exposure supports an independent movement disorder, while chronology remains central.

Management

01Acute reactionRelieve dystonia and protect airwayFirst stepA painful patterned posture or oculogyric crisis begins soon after a dopamine blocker.+
  1. 11. Assess airway, breathing, swallowing and laryngeal involvement, stop further culprit doses and call emergency support when speech, stridor or ventilation is affected.
  2. 22. Administer the locally available parenteral anticholinergic, such as imported benztropine, and reassess both the dystonia and cardiorespiratory status.
  3. 33. Document the drug and reaction prominently, review continuing oral cover where indicated and notify the prescribing team before any rechallenge.
  4. 44. Reconsider seizure, tetany, strychnine toxicity and structural disease if the response or phenomenology is atypical.
02New restlessness or slownessSeparate adverse effect from illnessPacing, agitation, bradykinesia or rigidity emerges during psychiatric or antiemetic treatment.

Complications

01

Airway compromise

Acute laryngeal, pharyngeal or jaw dystonia can obstruct breathing or swallowing and requires emergency recognition and treatment.

02

Persistent tardive disability

Tardive dyskinesia may remain after withdrawal, affecting speech, eating, walking, appearance and social participation over time.

03

Falls, aspiration and pain

Rigidity, sedation, dysphagia and abnormal postures increase falls, aspiration, musculoskeletal pain, loss of mobility and functional dependence.

04

Psychiatric destabilisation

Abruptly stopping essential antipsychotic treatment can precipitate relapse, self-harm or admission, so movement and mental-health risks require coordinated decisions.

Monitoring and follow-up

  • Record a movement baseline before and during antipsychotic therapy, inspecting mouth, tongue, face, fingers, trunk and gait rather than relying on spontaneous complaint.
  • During titration ask separately about inner restlessness, because akathisia can be intensely distressing despite modest visible movement.
  • Monitor temperature, autonomic state, hydration, CK and renal function urgently when rigidity or systemic illness suggests neuroleptic malignant syndrome.
  • Follow mental state, sleep, adherence and relapse warning signs alongside neurological change during any antipsychotic reduction or switch.
  • Measure tardive treatment against speech, eating, walking, pain and social participation, while tracking depression, parkinsonism and cardiac adverse effects.

Special situations

Akathisia feels worse

The subjective drive to move may be more distressing than pacing looks and has important links to treatment refusal, aggression and suicidal thinking.

Dose increase can mask tardive movement

More dopamine blockade may temporarily suppress dyskinesia, creating false improvement while increasing cumulative exposure and future persistence.

Antiemetics count

Metoclopramide and prochlorperazine are dopamine blockers, so an acute neck spasm or delayed oral movement may originate outside psychiatric prescribing.

Parkinsonism can unmask disease

A medicine may reveal latent Parkinson disease rather than being the sole cause, particularly when asymmetry and progression continue after withdrawal.

Anticholinergics are syndrome-specific

They rapidly treat acute dystonia but can worsen cognition, constipation, urinary retention and tardive dyskinesia when continued without a clear indication.

Common pitfalls

  1. 01

    Labelling akathisia agitation may prompt a higher antipsychotic dose, intensifying restlessness and suicide risk.

  2. 02

    Missing a dopamine-blocking antiemetic in medication reconciliation can lead to unnecessary neurological investigation and repeat exposure.

  3. 03

    Continuing procyclidine indefinitely for tardive dyskinesia can worsen the movement and add a major anticholinergic burden.

  4. 04

    Stopping an essential antipsychotic abruptly outside an emergency can precipitate relapse and destroy trust in management of the adverse effect.

  5. 05

    Using creatine kinase as the sole test for neuroleptic malignant syndrome delays treatment of a clinical emergency when the result is initially modest.

JurisdictionUnited Kingdom
  • Management starts by identifying the syndrome, reviewing dose and indication, and reducing, stopping or switching collaboratively; abrupt antipsychotic withdrawal can destabilise serious mental illness.
  • Anticholinergics treat acute dystonia and sometimes short-term parkinsonism but can worsen tardive dyskinesia and cause cognitive, urinary, ocular and gastrointestinal harm.
  • Persistent tardive syndromes require specialist psychiatry and movement-disorder input for lowest-risk antipsychotic strategy and possible VMAT2-directed treatment.
    • Interpretation and limitations
    Recovery may take weeks or months. Persistent asymmetric bradykinesia, non-motor Parkinson features or progression merits movement-disorder review and selected dopaminergic imaging.
  • 05
    ECG and physical-health monitoring
    Why
    Support safe antipsychotic or beta-blocker adjustment and quantify wider treatment burden.
    Interpretation and limitations
    QT, pulse, blood pressure, weight, glycaemia and lipids influence selection but do not replace movement surveillance. Use the current psychiatric protocol and medicine-specific risks.
    • +
    1. 11. Ask explicitly about inner restlessness and relief with movement, then examine bradykinesia, rigidity, tremor, affect and cognition.
    2. 22. Map onset to dose, depot and interacting medicines and assess suicidality, falls, swallowing and ability to engage with care.
    3. 33. Agree dose reduction, switch or cautious symptomatic treatment with the mental-health prescriber, avoiding abrupt destabilising cessation when no emergency exists.
    4. 44. Review after an adequate washout trajectory and refer persistent, progressive or asymmetric signs for neurological assessment.
    03TardiveReduce cumulative harmDelayed repetitive dyskinetic or dystonic movements persist during or after dopamine blockade.+
    1. 11. Confirm the phenomenology and quantify functional impact with baseline video or a structured scale, checking dentures and other mimics.
    2. 22. Review every dopamine blocker and anticholinergic, the ongoing psychiatric indication and previous relapse history in a shared multidisciplinary meeting.
    3. 33. Use the minimum effective exposure, consider a lower-risk antipsychotic and seek movement-disorder advice for disabling persistent symptoms or VMAT2 treatment.
    4. 44. Monitor both movement and mental state through any gradual change, explaining that symptoms may persist or transiently unmask after reduction.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Rapidly reverses acute dopamine-blocker-related dystonic spasm and can be life-saving when laryngeal muscles are involved.

    Imported benztropine for an acute dystonic reaction

    An adult may receive 1–2 mg IM or IV, with reassessment before a repeat at 30 minutes after IM or 10 minutes after IV administration. As an explicitly prescribed example, 1–2 mg IM repeated once gives a maximum of 4 mg in 24 hours; check the imported product and individual authorisation.

    This UK-unlicensed injection replaces discontinued procyclidine injection. Check the imported formulation and total anticholinergic exposure; maintain airway surveillance and watch delirium, tachycardia, urinary retention and glaucoma risk.

    Can reduce antipsychotic-induced akathisia when dose reduction or switching is insufficient or cannot occur immediately.

    Propranolol for selected akathisia

    After cardiovascular assessment, a specialist may start 10 mg two or three times daily and titrate cautiously to subjective and objective response under local guidance.

    Avoid in asthma, bradycardia, hypotension or significant conduction disease and consider masking of hypoglycaemia. It does not replace urgent assessment of suicidal distress.

    Reduces presynaptic monoamine packaging and may suppress functionally disabling persistent tardive movements when exposure optimisation is insufficient.

    VMAT2-directed treatment for tardive dyskinesia

    Choice, starting dose and titration depend on the commissioned specialist medicine and current formulary; treatment should occur through movement-disorder and psychiatry services with a documented baseline scale.

    Availability and licensing differ between agents. Monitor depression, suicidality, sedation, parkinsonism, akathisia, QT risk and interactions, and preserve necessary psychiatric treatment.